AlphaCrest Capital Management LLC Invests $577,000 in Myriad Genetics, Inc. (NASDAQ:MYGN)

Posted by Defense World Staff on Mar 9th, 2023

AlphaCrest Capital Management LLC bought a new position in Myriad Genetics, Inc. (NASDAQ:MYGN – Get Rating) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 30,238 shares of the company’s stock, valued at approximately $577,000.

Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada grew its holdings in Myriad Genetics by 29.0% during the 3rd quarter. Royal Bank of Canada now owns 2,339 shares of the company’s stock valued at $44,000 after purchasing an additional 526 shares during the last quarter. Point72 Hong Kong Ltd grew its holdings in Myriad Genetics by 722.8% during the 2nd quarter. Point72 Hong Kong Ltd now owns 3,217 shares of the company’s stock valued at $58,000 after purchasing an additional 2,826 shares during the last quarter. Ronald Blue Trust Inc. bought a new position in Myriad Genetics during the 2nd quarter valued at about $92,000. US Bancorp DE grew its holdings in Myriad Genetics by 14.6% during the 1st quarter. US Bancorp DE now owns 4,243 shares of the company’s stock valued at $108,000 after purchasing an additional 541 shares during the last quarter. Finally, CWM LLC grew its holdings in Myriad Genetics by 17.8% during the 3rd quarter. CWM LLC now owns 4,291 shares of the company’s stock valued at $82,000 after purchasing an additional 648 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors.

Insider Transactions at Myriad Genetics

In other news, CFO Richard Bryan Riggsbee sold 9,400 shares of the company’s stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $20.04, for a total value of $188,376.00. Following the completion of the sale, the chief financial officer now owns 364,107 shares of the company’s stock, valued at approximately $7,296,704.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 30,000 shares of company stock valued at $503,382. Company insiders own 1.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on MYGN. Stephens upped their price target on shares of Myriad Genetics from $17.00 to $24.00 and gave the company an “equal weight” rating in a report on Monday. Raymond James upped their price target on shares of Myriad Genetics from $25.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.20.

Myriad Genetics Price Performance

Myriad Genetics stock opened at $21.85 on Thursday. Myriad Genetics, Inc. has a 1 year low of $13.92 and a 1 year high of $28.18. The firm has a 50-day moving average of $19.02 and a two-hundred day moving average of $19.42.

Myriad Genetics Company Profile

(Get Rating)

Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk of developing a disease later in life.